Fig. 7: JNK signaling pathway activates the expression of STC1.
From: Stanniocalcin 1 promotes lung metastasis of breast cancer by enhancing EGFR–ERK–S100A4 signaling
A Western blot analysis of MAPK signaling pathway in MDA-MB-231 and LM2. B IHC staining of p-ERK and p-JNK in primary tumors and lung metastases formed by MDA-MB-231 cells. C Western blot analysis of STC1 in LM2 treated with MAPK signaling pathway inhibitor (10 μM) for 24 h. D RT-qPCR was performed to detect the relative expression of STC1 mRNA in LM2 treated with JNK signaling pathway inhibitor SP600125 (10 μM). E Correlation analysis of STC1 and JUN mRNA expression in metastatic lesions of breast cancer patients (data from GSE14020). F Schematic diagram of STC1 promoter displaying locations of primer pairs, covering c-Jun binding sites, which were used for qPCR analysis following chromatin immunoprecipitation with an antibody against c-Jun (left). The qPCR analysis of STC1 promoter fragments pulled down by c-Jun and IgG antibodies in chromatin immunoprecipitation (right). The p values were obtained by unpaired t-test or one-way ANOVA test with Dunnett’s multiple comparisons test or Pearson correlation analysis. Scale bars, 100 μm. STC1 stanniocalcin 1, IHC immunohistochemistry, ChIP chromatin immunoprecipitation. ns no significance, p > 0.05; **p < 0.01; ***p < 0.001.
